Allurion publishes study showing improvement in obesity-related co-morbidities

Allurion Technologies announced the publication of a randomized, double-blind study in Obesity Surgery that demonstrated significant reductions in type 2 diabetes, hypertension, and obstructive sleep apnea in just 4 months on the Allurion Program. These results improved with the addition of oral GLP-1 agonist semaglutide. In the study, 115 patients were randomized to either the Allurion Program with or without oral semaglutide and followed for 4 months. In patients randomized to the Allurion Program alone, weight loss was 13.7% at 4 months and resolution of type 2 diabetes, hypertension, and obstructive sleep apnea was observed in 55.5%, 58.8%, and 57.8%, respectively. Weight loss improved to 17.6% in the group treated with the Allurion Program and oral semaglutide and co-morbidity resolution improved to 64.7%, 64.3%, and 72%, respectively. “We have been extremely pleased with the results we are seeing in medically complex patients with the Allurion Program, especially the speed with which co-morbidities resolve,” said Mohit Bhandari, M.D., President of IRCAD India and senior author on the study. “We have seen that oral GLP-1 agonists alone are often insufficient to generate such significant results but using them as a tool to augment the results of the Allurion Program could be a promising treatment approach in the future.” Allurion recently published findings indicating that providers are interested in combining the Allurion Program with anti-obesity medications and that the rise of GLP-1 agonists has increased patient enquiries and boosted awareness of weight loss treatments like the Allurion Program.